Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 8;28(1):64-76.
eCollection 2017 Mar.

The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies

Affiliations

The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies

A B Burlina et al. EJIFCC. .

Abstract

Biogenic amine defects constitute a complex and expanding group of neurotransmitter disorders affecting cognitive, motor and autonomic system development, mostly in the pediatric age. In recent years different enzymatic defects have been identified impairing the tetrahydrobiopterin cofactor pathway and/or biogenic amine synthesis, catabolism and transport, with subsequent new disease entities described. The lumbar puncture, with subsequent withdrawal of cerebrospinal fluid (CSF), remains a key step in the diagnostic procedure. Due to the specific nature of CSF, timing of analysis, sample collection and storage, technical issues of the analytic process are still crucial for the diagnosis and follow-up of patients. A progressive approach to the diagnosis of biogenic amine defects is presented, pointing out criticalities and difficulties concerning sample collection and results interpretation, especially due to the increasing reports of secondary neurotransmitter alterations that, at present, constitute a challenge.

Keywords: cerebrospinal fluid; monoamine neurotransmitter deficiencies; tetrahydrobiopterin defects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biochemical pathways involving dopamine, serotonin, epinephrine, norepinephrine, and the cofactor BH4
Figure 2
Figure 2
Example chromatograms

Similar articles

Cited by

References

    1. Hyland K. (1999) Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism, Sem Perinatol 23,2:194-203. - PubMed
    1. Hyland K. (2008) Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid, Clin Chem 54(4):633-641. - PubMed
    1. Ng J, Papandreou A, Heales SJ, Kurian MA. (2015) Monoamine neurotransmitter disorders – clinical advances and future perspectives, Nat Rev Neurol 11(10):567-584 - PubMed
    1. Ormazabal A, García-Cazorla A, Fernández Y, Fernández-Álvarez E, Campistol J, Artuch R. (2005) HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins, J Neurosci Method 142:153-158. - PubMed
    1. García-Cazorla A, Serrano M, Pérez-Dueñas B, González V, Ormazábal A, Pineda M, Fernándz-Alvarez E, Campistol JMD, Artuch RMD. (2007) Secondary abnormalities of neurotransmitters in infants with neurological disorders, Dev Med Child Neurol 49:740-744 - PubMed

LinkOut - more resources